Achieve Life Sciences Reports Rising Losses Amid Promising Drug Development for Smoking Cessation

Company Overview:

Achieve Life Sciences, Inc. (NASDAQ: ACHV) is a late-stage clinical specialty pharmaceutical company dedicated to addressing nicotine dependence through its sole product candidate, cytisinicline. Located in Bothell, WA, and Vancouver, Canada, the company is primarily focused on smoking cessation and vaping cessation products.

Key Financial Highlights (as of June 30, 2025):

• Net Loss: $25.5 million for the six months ended June 30, 2025, compared to $14.9 million for the same period in 2024.
• Cash and Cash Equivalents: $51.9 million as of June 30, 2025.
• Total Assets: $58.9 million, a significant increase from $38.6 million at the end of 2024.
• Accumulated deficit: $231.1 million.
• Positive working capital balance of $48.3 million.

Income Statement Highlights:

• Research and Development Expenses: Increased to $6.7 million for Q2 2025 from $5.1 million in Q2 2024, largely due to costs associated with the ORCA-OL safety trial.
• General and Administrative Expenses: Grew to $5.9 million for Q2 2025 compared to $3.3 million in Q2 2024, attributed to higher employee costs and commercial launch preparations.
• Interest Income: Decreased to $0.2 million in Q2 2025 from $0.8 million in Q2 2024 due to lower cash balances and interest rates.
• Interest Expense: Declined to $0.2 million in Q2 2025 from $0.8 million in Q2 2024, attributed to a lower principal balance on debt.
• Comprehensive Loss: Comprehensive loss totaled $12.7 million for Q2 2025 versus $8.5 million in Q2 2024.

Recent Developments:

• In June 2025, the company submitted a New Drug Application (NDA) to the FDA for cytisinicline aimed at smoking cessation.
• Breakthrough Therapy designation received for cytisinicline for vaping cessation in 2024, expediting regulatory review and development.
• Public offerings in February and June 2025 raised substantial capital, aiding in ongoing operations and clinical trials.

Positive Aspects:

• Strong cash position with $51.9 million, supporting operational needs and potential commercialization efforts.
• Increased interest from regulatory authorities, as indicated by the Breakthrough Therapy designations, enhancing prospects for approval.

Negative Aspects:

• Significant ongoing losses, with a net loss margin that complicates funding and operational sustainability.
• Reliance on third-party manufacturers like Sopharma creates risks regarding the consistency of supply and regulatory compliance.
• Potential liabilities associated with product candidate development, including market acceptance and competition concerns.

Outlook:

Achieve Life Sciences is positioned for compelling growth contingent upon the successful approval and market entry of cytisinicline. However, reliance on external manufacturers and ongoing financial losses pose significant risks to its growth trajectory.